2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
6
Neoplasms
6
Pulmonary Embolism
5
Thromboembolism
3
Lung Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled